National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 41 of 66
Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer
NCT00354250
AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
NCT00321724
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
NCT00357305
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
NCT00328861
Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00316849
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
NCT00337129
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
NCT00354185
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
NCT00326872
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
NCT00326898
Benign Reproductive Tissue Analysis for Endometrial Cancer Markers
NCT00481754
Isolation and Characterization of Mammary Stem Cells
NCT00340392
SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT00337194
Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
NCT00331344
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
NCT00349206
Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
NCT00278343
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
NCT00331643
Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
NCT00314106
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
NCT00334893
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
NCT00335764
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
NCT00329719
Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer
NCT00304460
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
NCT00331682
AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer
NCT00245063
Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00301964
S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
NCT00217620
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
NCT00316953
Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors
NCT00324480
Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma
NCT00295984
Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00109824
Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia
NCT00335504
Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00253578
Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
NCT00302159
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
NCT00326664
Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer
NCT00330161
Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors
NCT00331955
Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies
NCT00335998
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
NCT00348985
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes
NCT00331513
Actigraph Accelerometer Validation Study
NCT00342212
AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer
NCT00303862
Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
NCT00301795
Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
NCT00324740
Thyroid Abnormalities Associated With Exposure to Atmospheric Emissions of Radioactive Iodine
NCT00342693
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
NCT00305864
Natural History Study of Moles and Suspicious Melanoma
NCT00288938
BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma
NCT00287495
O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors
NCT00275002
Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT00324870
Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery
NCT00305877
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
NCT00108732
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.